CN112512546A - 心脏特异性靶向肽(ctp)、其组合物和用途 - Google Patents

心脏特异性靶向肽(ctp)、其组合物和用途 Download PDF

Info

Publication number
CN112512546A
CN112512546A CN201980049263.2A CN201980049263A CN112512546A CN 112512546 A CN112512546 A CN 112512546A CN 201980049263 A CN201980049263 A CN 201980049263A CN 112512546 A CN112512546 A CN 112512546A
Authority
CN
China
Prior art keywords
ctp
peptide
seq
xaa
cargo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980049263.2A
Other languages
English (en)
Chinese (zh)
Inventor
莫里哈·扎西得
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of CN112512546A publication Critical patent/CN112512546A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99003—Heme oxygenase (1.14.99.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980049263.2A 2018-05-23 2019-05-22 心脏特异性靶向肽(ctp)、其组合物和用途 Pending CN112512546A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862675307P 2018-05-23 2018-05-23
US62/675,307 2018-05-23
US201862778033P 2018-12-11 2018-12-11
US62/778,033 2018-12-11
US201962811077P 2019-02-27 2019-02-27
US62/811,077 2019-02-27
PCT/US2019/033551 WO2019226785A1 (en) 2018-05-23 2019-05-22 Cardiac-specific targeting-peptide (ctp), compositions, and uses thereof

Publications (1)

Publication Number Publication Date
CN112512546A true CN112512546A (zh) 2021-03-16

Family

ID=68617073

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980049263.2A Pending CN112512546A (zh) 2018-05-23 2019-05-22 心脏特异性靶向肽(ctp)、其组合物和用途

Country Status (8)

Country Link
US (2) US20210206805A1 (https=)
EP (1) EP3811451A4 (https=)
JP (1) JP2021525246A (https=)
KR (1) KR20210022575A (https=)
CN (1) CN112512546A (https=)
AU (1) AU2019275044B2 (https=)
CA (1) CA3100943A1 (https=)
WO (1) WO2019226785A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020210712A2 (en) 2019-04-10 2020-10-15 Coralluma Llc. Ir700 nanocompositions for cardiac therapies and applications
WO2021087037A1 (en) * 2019-10-29 2021-05-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Lung-specific targeting-peptide (ltp), compositions, and uses thereof
EP4531869A2 (en) * 2022-05-31 2025-04-09 Georgetown University Use of conjugates of microrna and cardiac targeting peptides for treating heart failure
AU2024314139A1 (en) 2023-06-20 2026-01-08 Kuva Labs Inc. Methods for magnetic resonance molecular imaging of nanoconstructs and uses thereof
ES2953301B2 (es) * 2023-09-25 2024-06-03 Univ Madrid Complutense Péptido para el tratamiento de enfermedades cardiacas
WO2025106145A1 (en) * 2023-11-13 2025-05-22 Mayo Foundation For Medical Education And Research Hybrid form of cardiac targeting peptide with increased serum stability and enhanced cardiomyocyte targeting

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649614A (zh) * 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
CN1658889A (zh) * 2002-04-15 2005-08-24 联邦高等教育系统匹兹堡大学 治疗肠梗阻的方法
CN1812776A (zh) * 2003-05-21 2006-08-02 得克萨斯州大学系统董事会 抑制蛋白激酶c－mu(pkd)用作心脏肥大和心力衰竭的疗法
CN1938042A (zh) * 2004-01-23 2007-03-28 科内尔研究基金会 用于减轻氧化性损伤的方法
US20120244136A1 (en) * 2010-10-14 2012-09-27 Paul David Robbins Cardiac-Specific Protein Targeting Domain
CN102781965A (zh) * 2009-10-06 2012-11-14 安吉奥开米公司 用于转运治疗剂的组合物和方法
US20150297742A1 (en) * 2012-12-05 2015-10-22 Ruprecht-Karls-Universitat Conjugates of Proteins and Multivalent Cell-Penetrating Peptides and Their Uses
US20150307582A1 (en) * 2012-12-10 2015-10-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Engineered receptors and their use
US20150328315A1 (en) * 2012-04-23 2015-11-19 The Regents Of The University Of Michigan Systems and methods for targeted imaging and ablation of cardiac cells
WO2018090042A1 (en) * 2016-11-14 2018-05-17 Renova Therapeutics, Inc. Methods of treating heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063576A (en) * 1998-06-29 2000-05-16 University Of Utah Research Foundation Actin mutations in dilated cardiomyopathy, a heritable form of heart failure
US8460658B2 (en) * 2003-10-10 2013-06-11 Alchemia Oncology Pty Limited Method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same
WO2010033868A2 (en) * 2008-09-19 2010-03-25 Taligen Therapeutics, Inc. Ligand-specific non-antibody compounds that inhibit cr2 activation and methods of use thereof
US9550981B2 (en) * 2014-01-22 2017-01-24 University Of Washington Modified tafazzin proteins and methods of making and using the same

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649614A (zh) * 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
CN1658889A (zh) * 2002-04-15 2005-08-24 联邦高等教育系统匹兹堡大学 治疗肠梗阻的方法
CN1812776A (zh) * 2003-05-21 2006-08-02 得克萨斯州大学系统董事会 抑制蛋白激酶c－mu(pkd)用作心脏肥大和心力衰竭的疗法
CN1938042A (zh) * 2004-01-23 2007-03-28 科内尔研究基金会 用于减轻氧化性损伤的方法
CN102781965A (zh) * 2009-10-06 2012-11-14 安吉奥开米公司 用于转运治疗剂的组合物和方法
US20120244136A1 (en) * 2010-10-14 2012-09-27 Paul David Robbins Cardiac-Specific Protein Targeting Domain
US20150328315A1 (en) * 2012-04-23 2015-11-19 The Regents Of The University Of Michigan Systems and methods for targeted imaging and ablation of cardiac cells
US20150297742A1 (en) * 2012-12-05 2015-10-22 Ruprecht-Karls-Universitat Conjugates of Proteins and Multivalent Cell-Penetrating Peptides and Their Uses
US20150307582A1 (en) * 2012-12-10 2015-10-29 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Engineered receptors and their use
WO2018090042A1 (en) * 2016-11-14 2018-05-17 Renova Therapeutics, Inc. Methods of treating heart failure

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CASTEL G等: "Phage display of combinatorial peptide libraries: application to antiviral research. Molecules", MOLECULES, vol. 16, no. 05, 26 April 2011 (2011-04-26), pages 3500 *
郭争荣等: "细胞穿透肽:一种新型非病毒载体", 中国生物工程杂志, vol. 36, no. 06, pages 100 *

Also Published As

Publication number Publication date
KR20210022575A (ko) 2021-03-03
JP2021525246A (ja) 2021-09-24
WO2019226785A1 (en) 2019-11-28
EP3811451A1 (en) 2021-04-28
AU2019275044B2 (en) 2025-06-26
AU2019275044A1 (en) 2020-12-17
EP3811451A4 (en) 2022-04-06
CA3100943A1 (en) 2019-11-28
US20230406882A1 (en) 2023-12-21
WO2019226785A8 (en) 2020-06-18
US20210206805A1 (en) 2021-07-08

Similar Documents

Publication Publication Date Title
CN112512546A (zh) 心脏特异性靶向肽(ctp)、其组合物和用途
US20230256063A1 (en) Formulations of biologics for intravesical instillation
JP2022081521A (ja) 膀胱内注入用の生物製剤の処方
CN116323649A (zh) 膜联蛋白a1 n-末端肽的制剂和方法
CN112969451A (zh) 使用α连接蛋白C端肽的纳米粒子制剂和方法
Kim et al. Peptide permeation enhancers for improving oral bioavailability of macromolecules
US20220315625A1 (en) Lung-specific targeting-peptide (ltp), compositions, and uses thereof
CN119285744A (zh) 逆向-反转肽
US20240197896A1 (en) Synthetic peptide shuttle agent bioconjugates for intracellular cargo delivery
EP2894161B1 (en) Peptide for inhibiting vascular endothelial growth factor receptor
US20250189516A1 (en) Phosphorylation of p53 as a prognostic or diagnostic marker for the treatment of senescent cells in a mammal
CN112020555A (zh) 肽及其应用
HK40044421A (en) Formulations of biologics for intravesical instillation
WO2025123051A1 (en) Non-naturally occurring melanocortin analogs and uses thereof for modulating weight gain
HK40099512A (en) Phosphorylation of p53 as a prognostic or diagnostic marker for the treatment of senescent cells in a mammal
HK1233178B (en) Formulations of biologics for intravesical instillation
HK1233178A1 (en) Formulations of biologics for intravesical instillation
Zahid Targeting the heart using in vivo phage display

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination